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Introduction
• Obstructive sleep apnea (OSA) is a common, yet serious condition1
– Repetitive nocturnal airway collapse, leading to cessation of breathing
– Associated with stroke, hypertension, arrhythmias, decreased cognitive 
function, and diminished quality of life2
• Diagnosis of OSA includes either a home or in-laboratory sleep study to establish 
the extent of airway obstruction
– Study results will typically report an apnea-hypopnea index (AHI), denoting 
severity of disease
– AHI – apnea and hypopnea events per hour
• Effective first-line treatments of OSA include continued positive airway pressure 
(CPAP) therapy or mandibular repositioning3
= Compliance!
Introduction
• Following failure of CPAP or mandibular device, 
several surgical manipulations for OSA treatment 
exist
• Procedures selected depend on location of obstruction 
and individual patient anatomy4
• Currently, a standard of care does not exist for the anesthetic approach 
utilized for OSA patients receiving surgery
• Two highly utilized general anesthetic agents were evaluated in this study: 
Total Intravenous Anesthesia (TIVA) and Sevoflurane Gas (SEVO)
• Conflicting literature exists as to which method is superior 
• Meta-analyses have shown that TIVA leads to faster recovery times with 
less postoperative nausea5
• Potential impacts on efficiency and cost of recovery care, and patient 
satisfaction
Objectives & Hypothesis
• Research Question: How does Total Intravenous Anesthesia (TIVA) 
compare with Sevoflurane Gas (SEVO) with respect to resultant 
postoperative experience and recovery time in OSA patients 
undergoing surgery?
• Hypothesis: OSA patients undergoing surgery will experience 
reduced postoperative nausea and faster recovery times following 
administration of TIVA compared with patients that receive SEVO.
Approach & Results
• Study design: Retrospective Cohort Study 
• Population: OSA patients undergoing corrective surgery (Jan. 2019-Dec 
2019)
– Surgeries included nasal surgeries, uvulopalatopharyngoplasty









• Intervention: Administration of TIVA with propofol + remifentanil
• Comparison: Outcomes of patients receiving SEVO
• All data was obtained from Epic medical history charts
– Outcomes collected included time-based measures (total surgery and 
anesthesia time, time to emergence, time to PACU phase I/II 
completion, and total recovery time), incidence of postoperative 
nausea
• Rationale behind this approach:
– Retrospective review of patients with known anesthesia modality 
– Appropriate time data was available to conclude if recovery times 
differed
– Adverse events and complications occurring weeks later were also 







• Methods of analysis:
– Analyses were performed using Graphpad Prism software 
using the following tests:
• Unpaired nonparametric Mann-Whitney U tests (time 
comparisons/demographics)
• Fischer’s Exact tests (categorical data)







Age 52.7 ± 11.2 years 55.4 ± 12.1 years P=.1265





Race 78% Caucasian (n=67)











BMI 31.1 ± 4.7 kg/m2 29.8 ± 3.6 kg/m2 P=.1424 
AHI 31.6 ± 24.9 30.5 ± 18.9 P=.8848 
OSA Severity
% Mild OSA
AHI  ≥5 - <15
% Moderate OSA
AHI  ≥15 - <30
% Severe OSA
AHI  ≥30
24% Mild OSA (n=21)
34% Moderate OSA (n=29)
42% Severe OSA (n=36)
19% Mild OSA (n=12)
37% Moderate OSA (n=23)


















Median PACU phase I time decreased with TIVA across all surgical 
subtypes. Total recovery decreased in all surgeries except UPPP.
UAS Median PACU phase I difference: 42.5 min (p<.001, 95% CI 20.00 - 61.00) 
UPPP Median PACU phase I difference: 36 min (p=.022, 95% CI 6.00 - 83.00)
Nasal Median PACU phase I difference: 35.5 min (p<.001, 95% CI 18.00 - 52.00)
Approach and Results
Median PACU phase I time decreased with TIVA across all 
severities of OSA with surgeries combined.
Mild Median PACU phase I difference: 23.5 min (p=.004, 95% CI 11.00 - 55.00) 
Moderate PACU phase I difference: 52 min (p=.004, 95% CI 11.00 - 63.00)
Severe Median PACU phase I difference: 47 min (p<.001, 95% 16.00 - 56.00)
Approach and Results
Logarithmic 2-fold AHI increases correlates with increased 
PACU phase I time in SEVO patients.
SEVO phase I time increase: 16.8 min (p<.001, 95% CI 9.2 to 22.4)
TIVA phase I time increase: 4.3 min (p=.489, 95% CI -7.9 to 16.5)
Approach and Results
Incidence of postoperative nausea and vomiting (PONV) 






Fischer’s Exact Test of PONV Incidence: p=.07
Conclusions
• Based on this retrospective cohort:
– Surgical OSA patients experience reduced recovery time 
with TIVA regardless of OSA severity or surgery received
– OSA patients receiving SEVO experience increased time 
spent in recovery with increasing OSA severity
– Incidence of PONV did not differ based on anesthesia 
received, but may do so with an increased sample size
• Overall, our findings of reduced recovery time after 
TIVA are consistent with meta-analyses of the general 
population5
• Implications of these findings may include improved 
efficiency of care delivery and patient satisfaction, and 
potentially reduced cost of recovery care
– Further studies are needed to confirm these impacts
Future Directions
• Extensions of this study include:
– Prospective RCT placing patients in either a TIVA or SEVO 
group
• More thorough assessment of postoperative pain and 
nausea
– Cost analysis of this cohort utilizing Jefferson financial data 
and billing to insurance 
– Assessment of TIVA vs. SEVO in non-OSA patients 
undergoing otolaryngologic procedures (tonsillectomy, 
rhinoplasty, facelift, etc.)
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